Pulsecare completes over 100M yuan funding round to accelerate multi-pipeline R&D and commercialization

On November 6, Pulsecare, an innovative medical device company specializing in cardiovascular multimodal therapeutic technologies and devices, announced the successful completion of a Series A+ financing round raising approximately RMB hundred million. This round was led by Oriza Seed with participation from Loyal Valley Capital, while existing shareholders Tianfeng Capital and Tsinghua Innovation Ventures continued their support. China Renaissance served as the exclusive financial advisor for this transaction.

This financing round fully demonstrates the capital market's strong recognition of Pulsecare's breakthrough innovations in cardiovascular intervention, its strategic development in cardiac electrophysiology, and the outstanding clinical value of NxPFA®—the world's first nanosecond pulsed field ablation (nsPFA) system. The raised funds will be primarily allocated to: accelerating commercial promotion of the core product NxPFA® Nanosecond Pulsed Field Ablation System; deepening the development of comprehensive cardiac electrophysiology solutions centered on nsPFA technology; and advancing multi-center registration clinical studies and subsequent regulatory submissions for the industry's first acoustically controlled renal artery ultrasound denervation (muRDN) system in interventional hypertension treatment.

Pulsecare's self-developed NxPFA® Nanosecond Pulsed Field Ablation System obtained marketing approval from China's National Medical Products Administration (NMPA) in July 2025, establishing itself as the world's first and only approved nanosecond pulsed field ablation (nsPFA) product. This milestone signifies the official arrival of pulsed field ablation in the PFA 3.0 era.

Leveraging two decades of expertise in high-voltage pulse technology, the NxPFA® system utilizes high-repetition-frequency nanosecond pulses to achieve pulmonary vein isolation via irreversible electroporation. It demonstrates superior performance to second-generation microsecond PFA (μsPFA) in safety, efficiency, and accessibility: significantly reducing neuromuscular stimulation for procedures under conscious sedation without general anesthesia; minimizing hemolysis and microbubble formation to lower thromboembolism and stroke risks; and enabling more uniform transmural ablation for improved acute and long-term success rates.

The NxPFA® system, integrating the nanosecond pulse energy from the MaviPulse® console with the superior tissue apposition of the InteShot® basket-shaped catheter, enables highly efficient operation and a shortened learning curve, thereby facilitating the broader adoption of PFA technology in primary healthcare settings. The SCENA-AF registry clinical study demonstrated that NxPFA® achieved 100% acute pulmonary vein isolation success, with a post-procedure one-year PPS success rate of 88.27%. No device-related serious adverse events were reported, confirming its strong safety and efficacy profile. The system has now initiated commercialization across multiple provinces and municipalities, offering a safer and more efficient therapeutic option for patients with paroxysmal atrial fibrillation.

Beyond the NxPFA® system, Pulsecare is accelerating the development of its integrated cardiac electrophysiology solution centered on the "3D Mapping + PFA + ICE" platform. The company's proprietary 3D mapping system utilizes magnetic-electric fusion positioning technology with 1mm spatial resolution, supporting rapid anatomy reconstruction, high-density mapping, and real-time catheter tracking. Its seamless integration with NxPFA® enables real-time visualization of ablation procedures, enhancing surgical precision and workflow efficiency while significantly reducing X-ray exposure —advancing the practice of "green electrophysiology." The intracardiac echocardiography (ICE) system is expected to receive NMPA registration by 2026.

Three systems work collaboratively to form a closed-loop of "precise navigation—real-time imaging—targeted ablation," effectively addressing the pain points of traditional ablation, such as reliance on experience, complex operations, and high radiation doses. This significantly lowers the learning curve for operators and accelerates the dissemination of technology. In the future, the company will focus on NxPFA® as the cornerstone to continuously advance the platform layout and commercial implementation, creating a China-developed electrophysiology solution with global competitiveness. This will realize a leap from single-product breakthroughs to system leadership.

In the field of interventional hypertension management, Pulsecare has achieved a significant milestone with its globally pioneering product, the muRDN™ Ultrasound Renal Artery Denervation System. In June 2025, the company successfully enrolled the first patient in the Modulation HTN-2 multicenter registration clinical study, marking the official commencement of the regulatory validation phase for this innovative technology.

Based on nearly 20 years of ultrasound technology accumulation, the muRDN system integrates an innovative energy control and safety monitoring system, which can complete bilateral renal artery nerve ablation within 10 minutes, marking a major breakthrough in the development of RDN technology. The system is also equipped with real-time temperature feedback and power adjustment mechanisms, which can dynamically monitor and adjust output energy to achieve intelligent protection of the vascular intima and comprehensively ensure treatment safety.

Looking ahead, with the accumulation of clinical data and subsequent market approval, the muRDN system will integrate with Pulsecare's commercially available NxPFA® to establish a "cardio-renal" intervention platform. This integrated approach will serve patients with atrial fibrillation and hypertension, driving the strategic evolution toward comprehensive cardiovascular management and providing hundreds of millions of patients worldwide with safer, more efficient, and minimally invasive treatment alternatives.